Last reviewed · How we verify
NCT01705548
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
NA trial testing Hypofractionated Radiosurgery in Metastatic Malignant Neoplasm to Brain in 25 participants. Completed in 18 September 2023.
11 April 2023
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 24 September 2012 |
| Primary completion | 11 April 2023 |
| Estimated completion | 18 September 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Hypofractionated Radiosurgery
Conditions studied
- Metastatic Malignant Neoplasm to Brain — all drugs for Metastatic Malignant Neoplasm to Brain →
- Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →
Sponsor
Emory University
Who can join
18 and older, any sex, with Metastatic Malignant Neoplasm to Brain or Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial studies the side effects and best dose of hypofractionated radiosurgery in treating patients with large brain metastasis. Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Giving fractionated stereotactic radiosurgery may kill more tumor cells.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The radiosurgery fractionation quandary: single fraction or hypofractionation?
Kirkpatrick JP, Soltys SG, Lo SS, Beal K, et al · · 2017 · cited 83× · PMID 28380634 · DOI 10.1093/neuonc/now301 -
Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation.
Eaton BR, Gebhardt B, Prabhu R, Shu HK, et al · · 2013 · cited 70× · PMID 23759065 · DOI 10.1186/1748-717x-8-135 -
A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis.
Remick JS, Kowalski E, Khairnar R, Sun K, et al · · 2020 · cited 38× · PMID 32466775 · DOI 10.1186/s13014-020-01522-6
Verify or expand the search:
- PubMed search for NCT01705548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated Radiosurgery
Trials testing the same drug.
- NCT06914544 — Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III) · NA · not yet recruiting
- NCT03795337 — Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-II) · NA · unknown
Other recruiting trials for Metastatic Malignant Neoplasm to Brain
Currently open trials in the same condition.
- NCT02896335 — Palbociclib and Pembrolizumab In Central Nervous System Metastases · Phase 2 · recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01705548 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01705548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing